Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 2, 2004, Pages 99-103

  Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NIFEDIPINE; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR;

AFRICAN AMERICAN; CHINESE; DNA FLANKING REGION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISPOSITION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FIRST PASS EFFECT; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NEGRO; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE MUCOSA;

BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROBABILITY; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; VARIATION (GENETICS);

EID: 3543009000     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.04.005     Document Type: Note

References (37)

1. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available at: http://www.imm.ki.se/CYPalleles/
2. Burk O., Wojnowski L. Cytochrome P4503A and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 369:2004;105-124
3. Thummel K.E., Kunze K.L., Shen D.D. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Del Rev. 27:1997;99-127
4. Thummel K.E., Wilkinson G.R. In vitro and in vivo interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 38:1998;389-430
5. Lin Y.S., Lockwood G.F., Graham M.A., Brian W.R., Loi C.-M., Dobrinska M.R., et al. In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 11:2001;781-791
6. Floyd M.D., Gervasini G., Masica A.L., Mayo G., George A.L. Jr, Bhat K., et al. Genotype phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 13:2003;595-606
7. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Del Rev. 54:2002;1271-1294
8. Ball S.E., Scatina J., Kao J., Ferron G.M., Fruncillo R., Mayer P., et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther. 66:1999;288-294
9. Xie H-G, Wood AJJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72
10. Wrighton S.A., Ring B.J., Watkins P.B., VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol. 36:1989;97-105
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
12. Lin Y.S., Dowling A.L.S., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 62:2002;162-172
13. Yu K-S, Cho J-Y, Jang I-J, Hong K-S, Chung J-Y, Kim J-R, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004;76:104-12
14. Shih P.-S., Huang J.-D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 30:2002;1491-1496
15. Fukuda T., Onishi S., Fukuen S., Ikenaga Y., Ohno M., Hoshino K., et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J. 4:2004;34-39
16. Koch I., Weil R., Wolbold R., Brockmöller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P4503A mRNA. Drug Metab Dispos. 30:2002;1108-1114
17. Westlind-Johnsson A., Malmebo S., Johansson A., Otter C., Andersson T.B., Johansson I., et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 31:2003;755-761
18. i values and impact of CYP3A5 expression. Drug Metab Dispos. 27:1999;180-187
19. Wandel C., Witte J.S., Hall J.M., Stein C.M., Wood A.J.J., Wilkinson G.R. CYP3A activity in African- and European-American men population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther. 68:2000;82-91
20. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529-38
21. Goh B.-C., Lee S.-C., Wang L.-Z., Fan L., Guo J.-Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 20:2002;3683-3690
22. Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004;75:516-28
23. Hesselink D.A., van Schaik R.H.N., van der Heiden I.P., van der Werf M., Smak P.J.H., Gregoor J.H.S., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 74:2003;245-254
24. Yates C.R., Zhang W., Song P., Li S., Gaber A.O., Kotb M., et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 43:2003;555-564
25. Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., Meyer D.E., Eldour D.C., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 14:2004;147-154
26. Anglicheau D, Thervet E, Etienne I, de Ligny BH, Le Meur Y, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004;75:422-33
27. Thervet E., Anglicheau D., King B., Schlageter M.H., Cassinat B., Beaune P., et al. Impact of cytochrome P4503A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 76:2003;1233-1235
28. Givens R.C., Lin Y.S., Dowling A.L., Thummel K.E., Lamba J.K., Schuetz E.G., et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 95:2003;1297-1300
29. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Bowman P., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 3:2003;477-483
30. Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B.P., et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol. 44:2004;135-140
31. Langaee T.Y., Givens R.C., Sloan A., Watkins P.B., Johnson J.A. Association of CYP3A5*3,*6 and*7 polymorphisms with hypertension. [abstract] Clin Pharmacol Ther. 75:2004;P13
32. Ho H., Pinto A., Hall S.D., Flockhart D.A., Li L., Skaar T., et al. The association between the CYP3A5 genotype and blood pressure. [abstract] Clin Pharmacol Ther. 75:2004;P61
33. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 90:1998;1225-1229
34. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 8:1999;901-905
35. Rebbeck T.R. More about modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. [letter] J Natl Cancer Inst. 92:2000;76
36. Plummer S.J., Conti D.V., Paris P.L., Curran A.P., Casey G., Witte J.S. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 12:2003;928-932
37. Schuetz E.G. Lessons from the CYP3A4 promoter. Mol Pharmacol. 65:2004;279-281